Table 2.
Univariate analysis of Progression-Free and Overall Survival.
| Factor | Progression-Free Survival |
Overall Survival |
||||||
|---|---|---|---|---|---|---|---|---|
| Day 100 | 1-Year | 3-Year | P | Day 100 | 1-Year | 3-Year | P | |
| Age (years) | NS | NS | ||||||
| <40 | 57% (20–94) | 29% (0–62) | 29% (0–62) | 71% (38–100) | 57% (20–94) | 29% (0–62) | ||
| 40–59 | 67% (47–87) | 24% (6–42) | 6% (0–17) | 81% (64–98) | 43% (22–64) | 17% (0–34) | ||
| ≥60 | 67% (40–93) | 25% (0–50) | 17% (0–38) | 83% (62–100) | 33% (7–60) | 17% (0–38) | ||
| CIBMTR disease risk | NS | NS | ||||||
| Low | 71% (38–100) | 29% (0–62) | 14% (0–40) | 100% | 29% (0–62) | 14% (0–40) | ||
| Intermediate | 89% (68–100) | 33% (3–64) | 22% (0–49) | 89% (68–100) | 67% (36–97) | 33% (3–64) | ||
| High | 50% (30–70) | 21% (5–37) | 10% (0–24) | 71% (53–89) | 38% (18–57) | 15% (0–30) | ||
| Disease status pre-NMAT | 0.075 | 0.025 | ||||||
| CR≥1 | 82% (59–100) | 36% (8–65) | 18% (0–41) | 100% | 46% (16–75) | 18% (0–41) | ||
| Relapse≥1 | 65% (42–87) | 29% (8–51) | 22% (1–43) | 77% (56–97) | 65% (42–87) | 34% (11–57) | ||
| Never in CR | 50% (22–78) | 8% (0–24) | 0% | 67% (40–93) | 8% (0–24) | 0% | ||
| KPS | 0.097 | 0.014 | ||||||
| 90–100 | 92% (78–100) | 39% (12–65) | 23% (0–46) | 100% | 54% (27–81) | 39% (13–65) | ||
| 80 | 58% (31–86) | 25% (0–50) | 17% (0–38) | 83% (62–100) | 58% (30–86) | 17% (0–38) | ||
| <80 | 40% (15–65) | 13% (0–31) | 0% | 60% (35–85) | 20% (0–40) | 13% (0–30) | ||
| Donor relation/HLA match | NS | NS | ||||||
| Matched related | 64% (39–89) | 43% (17–69) | 27% (3–51) | 79% (58–100) | 50% (24–76) | 36% (11–61) | ||
| Matched unrelated | 79% (57–100) | 21% (0–43) | 7% (0–21) | 86% (68–100) | 50% (24–76) | 7% (0–21) | ||
| HLA-mismatched | 42% (14–70) | 8% (0–24) | 8% (0–24) | 75% (50–100) | 25% (1–50) | 17% (0–38) | ||
| CMV R+/D− | 0.004 | <0.001 | ||||||
| R+/D− | 31% (6–56) | 8% (0–22) | 0% | 69% (44–94) | 8% (0–22) | 0% | ||
| Other | 82% (67–96) | 33% (16–51) | 21% (5–37) | 85% (72–98) | 59% (40–78) | 29% (12–46) | ||
KPS: Karnofsky Performance Score; CMV R+ indicates recipient is serologically IgG positive pre NMAT, CMV D− indicates donor is serologically IgG negative prior to stem cell collection, NS: not statistically significant P>0.1.